Name: 글로벌 시장 동향
SKU: PH7183
Availability: InStock

보고서 요약(국문)

개요
전 세계 파스 플라니티스 치료 시장은 2022년 YY억 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY억 달러에 이를 것으로 예상됩니다.
전 세계 파스 플라니티스 치료 시장은 여러 요인의 영향으로 상당한 성장과 변화를 보여왔습니다. 파스 플라니티스라고 불리는 지속성 중간 포도막염은 전신 질환이나 감염과 관련이 없습니다. 파스 플라니티스 환자는 드물게 증상을 경험하지만, 비문증이나 시력 저하를 호소할 수 있습니다. 일반적으로 통증이나 광공포증은 없습니다.
특히 개발도상국에서 정부 투자와 연구는 코르티코스테로이드나 면역억제제와 같은 신약의 활용을 촉진하고 전 세계 파스 플라니티스 치료 시장 성장을 견인할 것입니다. 여러 연구자들이 이러한 혁신적인 치료법을 개발하고 있으며 현재 임상 시험 단계에 있습니다.

시장 동향: 성장 동력 및 제약 요인
자금 조달 및 인수 합병 증가
선진국들은 높은 투자, 소득 수준 향상, 인프라 개발에 힘입어 의료 부문이 빠르게 발전하고 있습니다. 여러 국가에서 연구 활동 증가로 인해 편평상피종 치료에 대한 수요가 크게 증가했습니다. 다양한 국가 간의 협력, 인수 합병, 그리고 기술 발전을 동반한 신제품 출시가 시장 성장을 견인하는 중요한 요인이 될 것입니다.
2023년 7월 3일, 비아트리스(Viatris)의 글로벌 바이오시밀러 사업부가 비오콘 바이오로직스(Biocon Biologics)에 인수되었습니다. 비오콘 바이오로직스는 미국, 유럽 및 100여 개국에서 다수의 바이오시밀러 라이선스를 보유하고 있습니다. 비오콘 바이오로직스는 비아트리스의 바이오시밀러 사업부 인수를 통해 환자와 의료 전문가들에게 더욱 접근하기 쉽고 저렴한 치료 옵션을 제공할 수 있게 되었습니다.

유럽에서 5년, 캐나다에서 2년간 사용된 후, 바이오콘(Biocon Ltd)의 자회사인 바이오콘 바이오로직스(BBL)는 휴미라(Humira, 아달리무맙)의 바이오시밀러인 훌리오(HULIO, 아달리무맙-fkjp) 주사제가 미국에서도 사용 가능하게 되었다고 발표했습니다.
또한, 다양한 개발 목적을 위한 높은 수준의 연구와 함께 신기술 활용이 증가하고 있습니다. 섬모체염 환자 수의 증가와 혁신적인 치료법 개발을 위한 연구 증가는 섬모체염 치료 시장 성장을 견인하는 주요 요인이 될 것입니다.
섬모체염 치료제 관련 부작용
치료 방법과 관계없이 섬모체염 환자는 다발성 경화증 발병 위험이 높을 수 있으며, 항TNF 제제는 탈수초화를 유발할 수 있습니다. 따라서 섬모체염 환자에게 항TNF 제제를 투여하기 전에 최대한 주의를 기울이고 위험-이익 비율을 평가해야 합니다.

파스 플라니티스는 인터페론으로도 성공적으로 치료되었지만, 부작용으로 우울증이나 자살 충동이 나타날 수 있습니다. 백내장과 녹내장은 가장 흔하게 투여되는 스테로이드제의 부작용입니다.
세분화 분석
전 세계 파스 플라니티스 치료 시장은 약물, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
코르티코스테로이드 부문은 시장 점유율의 약 37%를 차지했습니다.
프레드니솔론 나트륨 인산염 또는 아세트산염 국소 치료제는 각각 1%를 차지합니다. 경구용 프레드니손과 함께 코르티코스테로이드 안구 주위 주사도 효과적입니다. 치료 옵션에는 트리암시놀론 아세토니드 유리체강내 주사가 포함됩니다.
스테로이드제는 대부분의 중간 포도막염 사례 치료에 사용될 수 있습니다. 프레드니솔론은 자주 사용되는 약물입니다. 스테로이드는 면역 체계의 정상적인 기능을 방해하여 염증을 유발하는 물질의 분비를 억제하는 방식으로 작용합니다.

2021년 11월 17일, 미국 식품의약국(FDA)은 아우로빈도 파마(Aurobindo Pharma Limited)의 프레드니손 정 USP 1mg에 대한 약식 신약 신청(AND)을 최종 승인했습니다. 아우로빈도 파마의 프레드니손 정 USP 1mg은 쉐링(Schering Corp., 쉐링 플라우(Schering Plough Corp.)의 자회사)의 메티코르텐 정과 동일한 참조 의약품(RLD)입니다.
지역별 시장 점유율
북미는 2022년 시장 점유율의 약 36%를 차지했습니다.
의료 분야에서 섬모체염 치료에 대한 수요가 증가함에 따라 북미 제조업체들은 사업 확장의 기회를 갖고 있습니다. 북미에는 많은 생산자와 공급업체가 있으며, 이 지역의 빠른 경제 성장으로 산업 생산이 확대되어 섬모체염 치료에 대한 수요를 견인하고 있습니다.

의료비 지출 증가, 연구 활동 확대, 기술 발전 및 다양한 종류의 약물 개발, 그리고 이 지역 전반에 걸친 바이오제약 또는 생명공학 기업 설립 증가는 이 지역의 편평족염 치료 시장 점유율 성장에 기여하고 있습니다. 다양한 신약 승인에 대한 인식이 높아짐에 따라 이 지역 시장은 성장하고 있습니다. 앞서 언급한 요소들은 북미가 세계에서 차지하는 지배적인 위치를 더욱 뒷받침합니다.
북미는 미국을 중심으로 전 세계 편평족염 치료 시장에서 핵심적인 역할을 계속하고 있습니다. 인프라 개발 및 투자를 장려하는 정부 정책과 기술 발전에 대한 집중은 미국 내 편평족염 치료 수요를 촉진했습니다. 미국은 편평족염 치료 수요를 자극하는 여러 정책 및 연구를 적극적으로 추진해 왔습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 전 세계 편평족염 치료 시장에 전례 없는 어려움을 초래했습니다. 각국이 봉쇄 조치, 공급망 차질, 경제 활동 감소에 직면하면서 다양한 의약품을 주요 소비하는 제약 부문은 상당한 타격을 입었습니다. 2020년 초부터 시작된 팬데믹의 광범위한 봉쇄와 제한 조치로 인해 전 세계적으로 여러 노력이 영향을 받았습니다.
주요 의료 및 제약 산업은 운영을 중단하고 COVID-19 관리에 집중하면서 파스 플라니티스 치료제 수요가 급감했습니다. 그러나 현재 여러 연구가 시작되었고 기업들은 제품 효능에 대한 임상 시험을 다시 시작했습니다. 전반적으로 팬데믹이 전 세계 파스 플라니티스 치료제 시장에 미치는 영향은 비교적 경미할 것으로 예상되며, 혁신적인 치료법에 대한 지속적인 수요와 연구로 인해 시장은 꾸준히 성장할 것으로 전망됩니다.

주요 동향
• 제네릭 의약품 및 바이오시밀러 분야의 선두 기업인 산도즈(Sandoz)에 따르면, 2023년 3월 21일 미국 식품의약국(FDA)은 산도즈의 바이오시밀러 하이리모즈(Hyrimoz, 아달리무맙-아다즈) 주사제의 구연산염 무첨가 고농도 제형(HCF)을 승인했습니다. 오리지널 의약품인 휴미라(Humira*, 아달리무맙)는 류마티스 관절염, 건선성 관절염, 소아 특발성 관절염, 강직성 척추염, 궤양성 대장염, 크론병, 건선 등 7가지 적응증에 사용됩니다. 아달리무맙 구연산염 무첨가 HCF(100mg/mL)는 이러한 질환 치료에 승인되었습니다.

• 2021년 3월 25일, 뉴저지에 본사를 둔 인수드 파마슈티컬스의 제네릭 자회사인 시로메드(Xiromed LLC)는 프릴로섹(Prilosec)의 제네릭 버전인 오메프라졸 서방형 캡슐 20mg을 출시했습니다. 프릴로섹과 같은 양성자 펌프 억제제는 성인과 소아의 위식도 역류 질환(GERD) 치료, 성인의 십이지장 궤양 및 위궤양 치료, 그리고 미란성 식도염의 치유 유지에 처방됩니다.
경쟁 환경
시장의 주요 글로벌 업체로는 테바 제약(Teva Pharmaceutical Industries Ltd.), 애브비(AbbVie Inc., Allergan), 아우로빈도 파마 USA(Aurobindo Pharma USA), 화이자(Pfizer Inc.), 제넨텍(Genentech, Inc.), 노바티스(Novartis AG), 로즈몬트 제약(Rosemont Pharmaceuticals Limited), 시로메드(Xiromed), 다케다 제약(Takeda Pharmaceutical Company Limited), 베링거인겔하임 제약(Boehringer Ingelheim Pharmaceuticals, Inc.) 등이 있습니다.
보고서 구매 이유

• 약물, 투여 경로, 유통 채널 및 지역별 글로벌 파스 플라니티스 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 파스 플라니티스 치료 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 파스 플라니티스 치료 시장 보고서는 약 61개의 표, 59개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global pars planitis treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global pars planitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A persistent intermediate uveitis called pars planitis has not been connected with any systemic illness or infection. Although pars planitis patients rarely experience symptoms, they could mention floaters or impaired vision. There is typically no pain or photophobia.
Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like corticosteroids or immunosuppressives and boost the global pars planitis treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.
Market Dynamics: Drivers & Restraints
Growing funding and acquisitions
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for pars planitis treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.
On July 3, 2023, the global biosimilars business of Viatris was recently acquired by Biocon Biologics, which has also obtained numerous biosimilar licenses in the United States, Europe, and more than 100 other nations. Biocon Biologics can now assist in supplying patients and medical professionals with additional accessible and inexpensive treatment alternatives thanks to the acquisition of Viatris' biosimilars business.
After five years of use in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a division of Biocon Ltd, announced that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), has become accessible to patients in the United States.
Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising pars planitis cases and increasing research for innovative treatment development will be a major factor driving the growth of the pars planitis treatment market.
Side effects associated with the pars planitis treatment drugs
Regardless of treatment, patients with pars planitis could be at a greater likelihood for getting multiple sclerosis and anti-TNF Drugs may predispose to demyelination. Therefore, utmost caution should be utilized and the risk-benefit ratio should be assessed before administering an anti-TNF drug to a patient with pars planitis.
Pars planitis has also been successfully treated with interferon, however side effects can include depression or suicidal thoughts. Cataracts and glaucoma are the side effects of steroids that are most frequently administered.
Segment Analysis
The global pars planitis treatment market is segmented based on drugs, route of administration, distribution channel and region.
Corticosteroids segment accounted for approximately 37% of market share
Prednisolone sodium phosphate or acetate topical treatment, both of which are 1%. Along with oral prednisone, periocular injections with corticosteroids are also beneficial. Treatment options include intravitreal injections of triamcinolone acetonide.
Steroid medications can be used to treat the majority of intermediate uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation.
On November 17, 2021, the U.S. Food and Drug Administration has given final approval to Aurobindo Pharma Limited's Abbreviated New Drug Application for Prednisone Tablets USP, 1mg. Prednisone Tablets USP, 1mg from Aurobindo Pharma are a reference-listed drug (RLD) identical to Meticorten Tablets from Schering Corp Sub Schering Plough Corp.
Geographical Penetration
North America accounted for around 36% of market share in 2022
Due to the rising need for pars planitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for pars planitis treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies and different classes of drug, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of pars planitis treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.
North America continues to be a key player in the global pars planitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for pars planitis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating pars planitis treatment demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global pars planitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.
Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for pars planitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global pars planitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.
Key Developments
• On March 21, 2023, the US Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) which is citrate-free of Sandoz's biosimilar Hyrimoz (adalimumab-adaz) injection, according to the company, a leader in generic drugs and biosimilars. The reference drug Humira* (adalimumab) covers seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, and plaque psoriasis. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat these conditions.
• On March 25, 2021, Omeprazole Prolonged Release Capsules, 20mg, a generic version of Prilosec, have been launched, according to Xiromed LLC, the generic branch of Insud Pharmaceuticals based in New Jersey. Proton pump inhibitors like Prilosec are prescribed for treating gastroesophageal reflux disease (GERD) in both adults and children as well as for treating duodenal and gastric ulcers in adults and maintaining the healing of erosive esophagitis.
Competitive Landscape
The major global players in the market include Teva Pharmaceutical Industries Ltd., AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim Pharmaceuticals, Inc. among others.
Why Purchase the Report?
• To visualize the global pars planitis treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pars planitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global pars planitis treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drugs
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing funding and acquisitions
4.1.1.2. Rising technological advancements and developments
4.1.2. Restraints
4.1.2.1. Side effects associated with the pars planitis drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. SWOT Analysis
5.6. Patent Analysis
5.7. Russia-Ukraine War Impact Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drugs
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Prednisone (Deltasone, Meticorten, Orasone)
7.2.4. Triamcinolone (Amcort)
7.2.5. Prednisolone 1% (Pred Forte)
7.3. Immunosuppressives
7.3.1. Methotrexate (Folex PFS, Rheumatrex)
7.3.2. Mycophenolate (CellCept, MMF, Myfortic)
7.3.3. Cyclosporine (Sandimmune, Neoral)
7.3.4. Azathioprine (Imuran)
7.4. Histamine H2-Receptor Antagonist
7.4.1. Cimetidine (Tagamet)
7.4.2. Ranitidine (Zantac)
7.5. Gastric Pump Inhibitors
7.5.1. Omeprazole (Prilosec)
7.5.2. Lansoprazole (Prevacid)
7.5.3. Esomeprazole magnesium (Nexium)
7.6. Tumor Necrosis Factor (TNF) inhibitors (DMARDs)
7.6.1. Adalimumab (Adalimumab-atto, Amjevita, Humira)
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Intravenous
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Teva Pharmaceutical Industries Ltd.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. AbbVie Inc. (Allergan)
12.3. Aurobindo Pharma USA
12.4. Pfizer Inc.
12.5. Genentech, Inc.
12.6. Novartis AG
12.7. Rosemont Pharmaceuticals Limited
12.8. Xiromed
12.9. Takeda Pharmaceutical Company Limited
12.10. Boehringer Ingelheim Pharmaceuticals, Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Teva Pharmaceutical Industries Ltd., 4. Key Developments, AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim Pharmaceuticals, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Pars Planitis Treatment Market Value, By Drugs, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Pars Planitis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Pars Planitis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Pars Planitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Pars Planitis Treatment Market Value, By Drugs, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 7 Global Pars Planitis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Pars Planitis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Pars Planitis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Pars Planitis Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 14 North America Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Pars Planitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 18 South America Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Pars Planitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 22 Europe Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Pars Planitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Pars Planitis Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Pars Planitis Treatment Market Value, By Drugs, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Pars Planitis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Pars Planitis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Teva Pharmaceutical Industries Ltd.: Overview

Table 33 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 34 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 35 AbbVie Inc. (Allergan): Overview

Table 36 AbbVie Inc. (Allergan): Product Portfolio

Table 37 AbbVie Inc. (Allergan): Key Developments

Table 38 Aurobindo Pharma USA: Overview

Table 39 Aurobindo Pharma USA: Product Portfolio

Table 40 Aurobindo Pharma USA: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Genentech, Inc.: Overview

Table 45 Genentech, Inc.: Product Portfolio

Table 46 Genentech, Inc.: Key Developments

Table 47 Novartis AG: Overview

Table 48 Novartis AG: Product Portfolio

Table 49 Novartis AG: Key Developments

Table 50 Rosemont Pharmaceuticals Limited: Overview

Table 51 Rosemont Pharmaceuticals Limited: Product Portfolio

Table 52 Rosemont Pharmaceuticals Limited: Key Developments

Table 53 Xiromed: Overview

Table 54 Xiromed: Product Portfolio

Table 55 Xiromed: Key Developments

Table 56 Takeda Pharmaceutical Company Limited: Overview

Table 57 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 58 Takeda Pharmaceutical Company Limited: Key Developments

Table 59 Boehringer Ingelheim Pharmaceuticals, Inc.: Overview

Table 60 Boehringer Ingelheim Pharmaceuticals, Inc.: Product Portfolio

Table 61 Boehringer Ingelheim Pharmaceuticals, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 3 Global Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Pars Planitis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Pars Planitis Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)

Figure 7 Corticosteroids Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Immunosuppressives Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Histamine H2-Receptor Antagonist Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Gastric Pump Inhibitors Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Tumor necrosis factor (TNF) inhibitors (DMARDs) Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Global Pars Planitis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 13 Oral Route of Administration in Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 14 Intravenous Route of Administration in Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Others Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Pars Planitis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital Pharmacies Distribution Channel in Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Retail Pharmacies Distribution Channel in Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Online Pharmacies Distribution Channel in Global Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Pars Planitis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 28 North America Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Pars Planitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 South America Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 33 South America Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Pars Planitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 38 Europe Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Pars Planitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 43 Asia-Pacific Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Pars Planitis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Pars Planitis Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Pars Planitis Treatment Market Share, By Drugs, 2022 & 2030 (%)

Figure 48 Middle East & Africa Pars Planitis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Pars Planitis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Teva Pharmaceutical Industries Ltd.: Financials

Figure 51 AbbVie Inc. (Allergan): Financials

Figure 52 Aurobindo Pharma USA: Financials

Figure 53 Pfizer Inc.: Financials

Figure 54 Genentech, Inc.: Financials

Figure 55 Novartis AG: Financials

Figure 56 Rosemont Pharmaceuticals Limited: Financials

Figure 57 Xiromed: Financials

Figure 58 Takeda Pharmaceutical Company Limited: Financials

Figure 59 Boehringer Ingelheim Pharmaceuticals, Inc.: Financials

글로벌 파스플래니티스 치료 시장 – 2023-2030

Global Pars Planitis Treatment Market -2023-2030